These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 10408499)

  • 21. Anti-HIV therapies early in the pipeline.
    Bartnof HS
    BETA; 1999; 12(4):57. PubMed ID: 11367256
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oligonucleotide ligation assay for detection of mutations associated with reverse transcriptase and protease inhibitor resistance in non-B subtypes and recombinant forms of human immunodeficiency virus type 1.
    Vega Y; Pérez-Alvárez L; Delgado E; Muñoz M; Casado G; Carmona R; Sierra M; Vázquez de Parga E; Pinilla M; García V; Medrano L; Contreras G; Thomson M; Nájera R
    J Clin Microbiol; 2005 Oct; 43(10):5301-4. PubMed ID: 16208003
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacological exposure and the development of drug resistance in HIV.
    Hoetelmans R
    Antivir Ther; 2001; 6 Suppl 2():37-47. PubMed ID: 11678477
    [No Abstract]   [Full Text] [Related]  

  • 24. Antiretroviral resistance testing comes of age.
    Hammer SM; Pedneault L
    Antivir Ther; 2000 Mar; 5(1):23-6. PubMed ID: 10846589
    [No Abstract]   [Full Text] [Related]  

  • 25. How good does your virus look in a bikini? Or, does viral fitness matter?
    Martinez LJ
    Res Initiat Treat Action; 1999 Oct; 5(4):15-7. PubMed ID: 11366938
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV-1 protease mutation 82M contributes to phenotypic resistance to protease inhibitors in subtype G.
    Palma AC; Covens K; Snoeck J; Vandamme AM; Camacho RJ; Van Laethem K
    J Antimicrob Chemother; 2012 May; 67(5):1075-9. PubMed ID: 22331593
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Limits of resistance testing.
    D'Aquila RT
    Antivir Ther; 2000 Mar; 5(1):71-6. PubMed ID: 10846596
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Invirase resistance/cross-resistance data released.
    AIDS Patient Care STDS; 1996 Jun; 10(3):185. PubMed ID: 11361626
    [No Abstract]   [Full Text] [Related]  

  • 29. Yeast cells as a tool for analysis of HIV-1 protease susceptibility to protease inhibitors, a comparative study.
    Ravaux I; Perrin-East C; Attias C; Cottalorda J; Durant J; Dellamonica P; Gluschankof P; Stein A; Tamalet C
    J Virol Methods; 2014 Jan; 195():180-4. PubMed ID: 24056262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Update of the drug resistance mutations in HIV-1: 2004.
    Johnson VA; Brun-Vézinet F; Clotet B; Conway B; D'Aquila RT; Demeter LM; Kuritzkes DR; Pillay D; Schapiro JM; Telenti A; Richman DD
    Top HIV Med; 2004; 12(4):119-24. PubMed ID: 15516709
    [No Abstract]   [Full Text] [Related]  

  • 31. Interpretation of genotypic HIV-1 resistance to darunavir and virological response: validation of available systems and of a new score.
    De Luca A; Di Giambenedetto S; Maserati R; Gianotti N; Narciso P; Antinori A; Di Perri G; Prosperi MC; Baldanti F; Micheli V; Zazzi M; Perno CF; Santoro MM; ;
    Antivir Ther; 2011; 16(4):489-97. PubMed ID: 21685536
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New data brings resistance testing closer to routine clinical use.
    Murphy MJ
    Fac Notes (New Orleans La); 1999; 11(3):6. PubMed ID: 11810872
    [No Abstract]   [Full Text] [Related]  

  • 33. Principles of HIV resistance testing and overview of assay performance characteristics.
    Richman DD
    Antivir Ther; 2000 Mar; 5(1):27-31. PubMed ID: 10846590
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Primary resistance to antiretroviral agents].
    Soriano V; María Miró J; Guerrero A
    Enferm Infecc Microbiol Clin; 2001 Feb; 19(Monografico):22-5. PubMed ID: 11428054
    [No Abstract]   [Full Text] [Related]  

  • 35. [Advances in novel anti-HIV-1 drugs and drug candidates: 2005-2008].
    Zheng PR; Xue H; Xiao ZY; Liu G
    Yao Xue Xue Bao; 2010 Feb; 45(2):154-64. PubMed ID: 21351426
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multi-drug resistant HIV-1.
    Omrani AS; Pillay D
    J Infect; 2000 Jul; 41(1):5-11. PubMed ID: 10942635
    [No Abstract]   [Full Text] [Related]  

  • 37. HIV drug-resistance cutoffs available.
    AIDS Read; 2000 Dec; 10(12):702. PubMed ID: 11189739
    [No Abstract]   [Full Text] [Related]  

  • 38. Primary drug resistance in antiretroviral-naïve injection drug users.
    Tossonian HK; Raffa JD; Grebely J; Viljoen M; Mead A; Khara M; McLean M; Krishnamurthy A; DeVlaming S; Conway B
    Int J Infect Dis; 2009 Sep; 13(5):577-83. PubMed ID: 19111493
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Characterization of resistance in HIV. Comparison of geno- and phenotypic resistance to HIV-1 protease inhibitors].
    Schmidt B; Walter H; Korn K
    Pharm Unserer Zeit; 2001; 30(3):228-32. PubMed ID: 11400672
    [No Abstract]   [Full Text] [Related]  

  • 40. Resistance testing.
    Munk B
    Posit Aware; 1997; 8(4):35-7. PubMed ID: 11364486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.